Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Concurrent Session 1: CAR-T and Directed T-cell Therapy-- Advancing Beyond B-ALL

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 3 of 3
Concurrent Session 1: CAR-T and Directed T-cell Therapy-- Advancing Beyond B-ALL
CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno
START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Concurrent Session 1: CAR-T and Directed T-cell Therapy-- Advancing Beyond B-ALL
  •  
  • Permission not
    granted for presentation
  •  
  •  
T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Concurrent Session 1: CAR-T and Directed T-cell Therapy-- Advancing Beyond B-ALL
Maximizing the potential of bispecific antibodies for cancer drug development
Paul W H I Parren
Leiden University Medical Center and Lava Therapeutics, Utrecht, Netherlands
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 3 of 3